Table 2 Preclinical studies investigating the effect of CBD on neuropathic and nociceptive pain in vivo

 De Gregorio et al., (2019) [51]

Wistar rats

SNI

5 mg·kg^-1·d^-1, s.c. 7 d

CBD sig. decreased mechanical allodynia on Tx day 7.

 Casey et al., (2017) [29]

C57BL/6 mice

CCI

30 mg·kg^-1, s.c.

CBD sig. decreased mechanical allodynia 2 h, but not 0.5, 1, 4 or 6 h, post-Tx compared to baseline.

0.01, 0.1, 1, 10 or 100 mg·kg^-1, s.c.

CBD dose-dependently decreased mechanical and cold allodynia.

 King et al., (2017) [101]

C57BL/6 mice

CT (Paclitaxel)

0.625–20 mg·kg^-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7

1 and 20 mg·kg^-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 9 and 14, but not 21.

CT (Oxaliplatin)

1.25–10 mg·kg^-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7

1.25–10 mg·kg^-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 2, 4, 7 and 10.

CT (Vincristine)

1.25–10 mg·kg^-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7

CBD did not attenuate the development of CT-induced mechanical allodynia measured on Tx days 5, 10, 15 and 22.

 Harris et al., (2016) [78]

C57BL/6 mice

CT (Cisplatin)

2 mg·kg^-1, i.p.

CBD sig. decreased tactile allodynia 1 h post-Tx.

0.5, 1 or 2 mg·kg^-1, i.p. 30 min prior to CT every second day for 12 d

CBD did not attenuate the development of CT-induced tactile allodynia measured on Tx days 6, 10 and 12.

 Ward et al., (2014) [187]

C57BL/6 mice

CT (Paclitaxel)

2.5 and 5 mg·kg^-1·d^-1 CBD attenuated the development of CT-induced mechanical allodynia.

 Toth et al., (2010) [174]

CD1 mice

STZ Diabetes

0.1, 1 or 2 mg·kg^-1·d^-1, i.n. 3 months

1 and 2 mg·kg^-1·d^-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 0.1 mg·kg^-1·d^-1 CBD.

2 mg·kg^-1·d^-1, i.n. 1 month

1, 10 or 20 mg·kg^-1·d^-1, i.p. 3 months

20 mg·kg^-1·d^-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 1 mg·kg^-1·d^-1 CBD.

20 mg·kg^-1·d^-1, i.p. 1 month

CBD did not alleviate developed thermal or tactile hypersensitivity.

 Costa et al., (2007) [41]

Wistar rats

CCI

2.5, 5, 10 or 20 mg·kg^-1·d^-1, oral 7 d

5, 10 and 20 mg·kg^-1·d^-1 CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7.

 Genaro et al., (2017) [70]

Wistar rats

Incision

0.3, 1, 3, 10 or 30 mg·kg^-1, i.p.

3 mg·kg^-1 CBD sig. decreased mechanical allodynia between 30- and 150-min post-Tx; 10 mg·kg^-1 CBD sig. decreased mechanical allodynia 60 min post-Tx, only.

 Hammell et al., (2016) [75]

Sprague-Dawley rats

FCA

0.6, 3.1, 6.2 or 62.3 mg·kg^-1·d^-1, t.c. 4 d

6.2 and 62.3 mg·kg^-1 CBD sig. decreased pain-related behaviour on Tx day 4 and thermal hyperalgesia on Tx days 2, 3 and 4.

 Costa et al., (2007) [41]

Wistar rats

FCA

20 mg·kg^-1·d^-1, oral 7 d

CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7.

 Costa et al., (2004) [39]

Wistar rats

Carrageenan

5, 7.5, 10, 20 and 40 mg·kg^-1, oral

5, 7.5, 10, 20 and 40 mg·kg^-1·d^-1 CBD sig. decreased thermal hyperalgesia 1–5 h post-Tx.

 Costa et al., (2004) [40]

Wistar rats

Carrageenan

10 mg·kg^-1, oral

CBD sig. decreased thermal hyperalgesia 1 h post-Tx.